摘要
目的观察和评价益肺通络方联合西药化疗方案治疗耐多药肺结核的疗效。方法将225例患者随机分为观察组124例采用益肺通络方联合西药化疗方案治疗,对照组101例采用单纯西药化疗方案治疗,观察两组治疗第3、6、9、12、15、18、21、24月的临床疗效及安全性。结果疗程结束时,观察组痰菌阴转率、中医症候学指标及免疫功能改善均优于对照组,其中痰结核菌转阴率(3、6月)、中医症候学指标(3、6、9月)及免疫学指标CD4比值(6月)观察组与对照组比较差异有统计学意义(P<0.05)。结论益肺通络方联合西药化疗方案治疗耐多药肺结核可促进痰菌阴转、症状改善及提高患者免疫功能,临床有效且安全,为耐多药肺结核患者的治疗选择了新路径,具有临床推广应用前景。
Objective To observe and evaluate the treatment effect of the Yifei Tongluo medicine combined with chemotherapy on multi-drug resistant tuberculosis. Methods The225 patients were randomly divided into treatment and control groups, 124 cases in the treatment group were given Yifei Tongluo prescription combined with anti-tuberculosis drug,101 cases in the control group given anti-tuberculosis drug. The clinical curative effect and security of the two groups at 3, 6, 9, 12, 15, 18, 21, 24 months were observed. Results The end of treatment, sputum conversion rate in the treatment group, clinical symptoms and immune function improvement were better than the control group, in which sputum conversion rate（3and 6 months） and clinical symptoms（3, 6, 9 months） and immune function improvement（6 months）. The difference between observation group and control group was statistically significant（P〈0.05）. Conclusion The combination chemotherapy Yifei Tongluo prescription in the treatment of MDR-TB can accelerate sputum negative conversion, improve the syndrome and immune function of patients. That showed effective and safe curative effect and offered new approach for multi-drug resistant tuberculosis patients. It had clinical application value.
出处
《湖南中医药大学学报》
CAS
2014年第9期46-50,共5页
Journal of Hunan University of Chinese Medicine
基金
国家"十二五"科技重大专项资助课题(2012ZX10005010-003-001)
关键词
耐多药肺结核
益肺通络方
西药化疗
临床研究
multi-drug resistant pulmonary tuberculosis
Yifei Tongluo prescription
chemotherapy
clinical study
